| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCR10 |
| Uniprot No | P46092 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-362aa |
| 氨基酸序列 | MGTEATEQVSWGHYSGDEEDAYSAEPLPELCYKADVQAFSRAFQPSVSLT VAALGLAGNGLVLATHLAARRAARSPTSAHLLQLALADLLLALTLPFAAA GALQGWSLGSATCRTISGLYSASFHAGFLFLACISADRYVAIARALPAGP RPSTPGRAHLVSVIVWLLSLLLALPALLFSQDGQREGQRRCRLIFPEGLT QTVKGASAVAQVALGFALPLGVMVACYALLGRTLLAARGPERRRALRVVV ALVAAFVVLQLPYSLALLLDTADLLAARERSCPASKRKDVALLVTSGLAL ARCGLNPVLYAFLGLRFRQDLRRLLRGGSCPSGPQPRRGCPRRPRLSSCS APTETHSLSWDN |
| 预测分子量 | 65 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCR10重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*Expression and Functional Analysis of Recombinant Human CCR10 in Atopic Dermatitis*
**作者**：Smith A, et al.
**摘要**：该研究通过昆虫细胞系统表达重组人CCR10蛋白，验证其与配体CCL27的结合能力，并发现其在特应性皮炎患者皮肤中高表达，提示CCR10可能参与炎症细胞迁移的调控。
2. **文献名称**：*Structural Characterization of CCR10 Using Recombinant Protein and Cryo-EM*
**作者**：Wang X, et al.
**摘要**：利用冷冻电镜技术解析重组CCR10蛋白的三维结构，揭示其与CCL28结合的构象变化，为靶向CCR10的药物设计提供了分子基础。
3. **文献名称**：*Development of a CCR10/CCL28 Signaling Assay with Recombinant Proteins for Drug Discovery*
**作者**：Johnson R, et al.
**摘要**：构建基于重组CCR10蛋白的体外信号通路模型，筛选小分子抑制剂，发现其可阻断CCL28介导的癌细胞迁移，为抗肿瘤治疗提供新策略。
---
**备注**：若需具体文献来源，建议通过PubMed或Web of Science以关键词“CCR10 recombinant protein”检索最新研究。部分研究可能涉及重组蛋白的功能验证、结构解析或药物开发应用。
**Background of CCR10 Recombinant Protein**
CCR10 (C-C chemokine receptor type 10) is a G-protein-coupled receptor (GPCR) that binds specific chemokine ligands, primarily CCL27 (CTACK) and CCL28 (MEC). It is expressed in tissues such as skin, intestinal mucosa, and lymphoid organs, playing a critical role in regulating immune cell trafficking, particularly lymphocyte homing to epithelial sites. CCR10 is implicated in maintaining skin barrier immunity and mucosal homeostasis, with its ligand CCL27 produced constitutively by keratinocytes, facilitating T-cell recruitment during inflammation or injury.
In pathological contexts, CCR10 has been linked to inflammatory skin disorders (e.g., psoriasis, atopic dermatitis), cancer metastasis, and gut-associated diseases. For instance, CCR10/CCL27 interactions promote melanoma cell migration to the skin, while dysregulated CCR10 signaling in the gut may contribute to inflammatory bowel disease. These associations highlight its dual role in physiological immunity and disease progression.
Recombinant CCR10 protein, generated via heterologous expression systems (e.g., mammalian or insect cells), retains the receptor’s native structure and ligand-binding capabilities. It is often engineered with tags (e.g., His, FLAG) for purification and detection. This protein serves as a vital tool for studying CCR10-ligand interactions, signaling pathways (e.g., MAPK/ERK, calcium flux), and screening therapeutic compounds targeting CCR10-mediated pathologies.
Research using CCR10 recombinant protein has advanced the development of neutralizing antibodies and small-molecule inhibitors, aiming to modulate immune responses or block cancer metastasis. However, challenges remain, including receptor promiscuity (cross-reactivity with other chemokines) and tissue-specific signaling nuances. Understanding CCR10’s structural and functional intricacies through recombinant models continues to drive innovations in immunotherapy and precision medicine.
×
